Principal Financial Group Inc. reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 119,510 shares of the company’s stock after selling 4,664 shares during the quarter. Principal Financial Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,103,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $106,000. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $129,000. Shelter Mutual Insurance Co acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $133,000. Finally, Fayez Sarofim & Co. acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $204,000. Institutional investors own 52.05% of the company’s stock.

Several analysts have recently commented on the company. Guggenheim assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday. They issued a “neutral” rating and a $16.00 price target for the company. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. Royal Bank of Canada set a $11.00 price target on Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Wednesday, November 29th. Mizuho raised their price target on Teva Pharmaceutical Industries from $12.00 to $16.00 and gave the company a “neutral” rating in a report on Wednesday, November 29th. Finally, BTIG Research set a $16.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Tuesday, November 28th. Seven analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average price target of $19.18.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down $0.05 during midday trading on Tuesday, hitting $16.39. The stock had a trading volume of 17,329,042 shares, compared to its average volume of 15,790,248. Teva Pharmaceutical Industries Limited has a 12 month low of $10.85 and a 12 month high of $38.31. The firm has a market capitalization of $16,316.96, a PE ratio of 3.71 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.07%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is -12.10%.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/principal-financial-group-inc-has-2-10-million-holdings-in-teva-pharmaceutical-industries-limited-teva/1759754.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with Analyst Ratings Network's FREE daily email newsletter.